Clinical characteristics of patients with newly diagnosed t-ALL, dn-ALL, or pm-ALL
| . | t-ALL (n = 116) . | dn-ALL (n = 100) . | pm-ALL (n = 20) . | P . |
|---|---|---|---|---|
| Females | 60 (51.7) | 35 (35) | 11 (55) | .03 |
| Race | .81 | |||
| White | 88 (85) | 85 (85) | 19 (95) | |
| African American | 8 (7) | 10 (10) | 1 (5) | |
| Hispanic | 4 (4) | 5 (5) | 0 | |
| Asian | 4 (4) | 0 | 0 | |
| Age at ALL, median (range), y | 61 (21-90) | 41.5 (18-79) | 66 (32-93) | <.001 |
| Interdiagnoses interval, median (range), y | 5 (0.5-35) | n/a | 8 (1-32) | .04 |
| First malignancy | n/a | .07 | ||
| Solid | 72 (62.1) | 17 (85) | ||
| Hematological | 44 (37.9) | 3 (15) | ||
| B-ALL | 107 (92) | 86 (86) | 18 (90) | .33 |
| WBC count, median (range), × 109/L | 5.67 (0.3-353.4) | 6.69 (0.3-366) | 4 (1-124.3) | .98 |
| Peripheral blasts, median (range), % | 23 (0-98) | 23 (0-96) | 23.1 (0-91) | .99 |
| Bone marrow blasts, median (range), % | 81.5 (0-99) | 87 (1-98) | 80 (0-98) | .26 |
| Extramedullary disease | 22 (19) | 21 (21) | 3 (20) | .94 |
| Cytogenetics | <.001 | |||
| Normal | 27 (26) | 32 (32) | 3 (11) | .33 |
| BCR-ABL | 26 (25) | 30 (30) | 7 (39) | .42 |
| MLLr | 14 (13) | 8 (8) | 0 | .34 |
| MDS-like* | 28 (27) | 7 (7) | 0 | <.001 |
| Other | 9 (9) | 23 (23) | 8 (44) | <.001 |
| First-line treatment | .08 | |||
| BFM based | 48 (41.4) | 47 (47) | 9 (45) | |
| Hyper-CVAD | 35 (30.2) | 43 (43) | 6 (30) | |
| Vincristine with or without prednisone | 9 (7.8) | 1 (1) | 3 (15) | |
| Other chemotherapy | 17 (14.6) | 9 (9) | 2 (10) | |
| No treatment | 4 (3.4) | 0 | 0 | |
| Unknown | 3 (2.6) | 0 | 0 | |
| Response to induction | .92 | |||
| CR | 81 (82) | 83 (83) | 14 (87.5) | |
| CRi | 5 (5) | 6 (6) | 0 | |
| Refractory | 13 (13) | 11 (11) | 2 (12.5) | |
| MRD status at response | .34 | |||
| Positive | 24 (51) | 10 (34) | 3 (37.5) | |
| Negative | 23 (49) | 19 (66) | 5 (62.5) | |
| Performance of HCT, n | 42 | 50 | 7 | .09 |
| In CR1 | 35 (30.2) | 42 (42) | 6 (30) | |
| In CR2 | 7 (6) | 8 (8) | 1 (5) | |
| Donor source, n | .29 | |||
| MUD | 18 | 28 | 3 | |
| MSD | 12 | 14 | 2 | |
| UCB | 5 | 0 | 1 | |
| Haploidentical | 2 | 7 | 0 | |
| Autologous | 0 | 1 | 1 | |
| Conditioning regimen | .34 | |||
| Myeloablative | 25 (78) | 36 (75) | 3 (50) | |
| Reduced intensity | 7 (22) | 12 (25) | 3 (50) |
| . | t-ALL (n = 116) . | dn-ALL (n = 100) . | pm-ALL (n = 20) . | P . |
|---|---|---|---|---|
| Females | 60 (51.7) | 35 (35) | 11 (55) | .03 |
| Race | .81 | |||
| White | 88 (85) | 85 (85) | 19 (95) | |
| African American | 8 (7) | 10 (10) | 1 (5) | |
| Hispanic | 4 (4) | 5 (5) | 0 | |
| Asian | 4 (4) | 0 | 0 | |
| Age at ALL, median (range), y | 61 (21-90) | 41.5 (18-79) | 66 (32-93) | <.001 |
| Interdiagnoses interval, median (range), y | 5 (0.5-35) | n/a | 8 (1-32) | .04 |
| First malignancy | n/a | .07 | ||
| Solid | 72 (62.1) | 17 (85) | ||
| Hematological | 44 (37.9) | 3 (15) | ||
| B-ALL | 107 (92) | 86 (86) | 18 (90) | .33 |
| WBC count, median (range), × 109/L | 5.67 (0.3-353.4) | 6.69 (0.3-366) | 4 (1-124.3) | .98 |
| Peripheral blasts, median (range), % | 23 (0-98) | 23 (0-96) | 23.1 (0-91) | .99 |
| Bone marrow blasts, median (range), % | 81.5 (0-99) | 87 (1-98) | 80 (0-98) | .26 |
| Extramedullary disease | 22 (19) | 21 (21) | 3 (20) | .94 |
| Cytogenetics | <.001 | |||
| Normal | 27 (26) | 32 (32) | 3 (11) | .33 |
| BCR-ABL | 26 (25) | 30 (30) | 7 (39) | .42 |
| MLLr | 14 (13) | 8 (8) | 0 | .34 |
| MDS-like* | 28 (27) | 7 (7) | 0 | <.001 |
| Other | 9 (9) | 23 (23) | 8 (44) | <.001 |
| First-line treatment | .08 | |||
| BFM based | 48 (41.4) | 47 (47) | 9 (45) | |
| Hyper-CVAD | 35 (30.2) | 43 (43) | 6 (30) | |
| Vincristine with or without prednisone | 9 (7.8) | 1 (1) | 3 (15) | |
| Other chemotherapy | 17 (14.6) | 9 (9) | 2 (10) | |
| No treatment | 4 (3.4) | 0 | 0 | |
| Unknown | 3 (2.6) | 0 | 0 | |
| Response to induction | .92 | |||
| CR | 81 (82) | 83 (83) | 14 (87.5) | |
| CRi | 5 (5) | 6 (6) | 0 | |
| Refractory | 13 (13) | 11 (11) | 2 (12.5) | |
| MRD status at response | .34 | |||
| Positive | 24 (51) | 10 (34) | 3 (37.5) | |
| Negative | 23 (49) | 19 (66) | 5 (62.5) | |
| Performance of HCT, n | 42 | 50 | 7 | .09 |
| In CR1 | 35 (30.2) | 42 (42) | 6 (30) | |
| In CR2 | 7 (6) | 8 (8) | 1 (5) | |
| Donor source, n | .29 | |||
| MUD | 18 | 28 | 3 | |
| MSD | 12 | 14 | 2 | |
| UCB | 5 | 0 | 1 | |
| Haploidentical | 2 | 7 | 0 | |
| Autologous | 0 | 1 | 1 | |
| Conditioning regimen | .34 | |||
| Myeloablative | 25 (78) | 36 (75) | 3 (50) | |
| Reduced intensity | 7 (22) | 12 (25) | 3 (50) |
Unless otherwise indicated, data are n (%).
B-ALL, B-cell ALL; MSD, matched sibling donor; MUD, matched unrelated donor; n/a, not applicable; UCB, umbilical cord blood transplant.
MDS-like cytogenetic abnormalities included deletions of chromosomes 5, 7, 11, 13, 17, and 20, as well as trisomy 8.